Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease
associated with dyspnoea, cough and impaired quality of life. Currently, the aims of patient …

Objective: Provide information for pharmacists on idiopathic pulmonary fibrosis (IPF) and its
treatment. Study Selection and Data Extraction: All articles with data from randomized …

Este resumen ejecutivo del Informe de 2017 de la Global Strategy for the Diagnosis,
Management, and Prevention of COPD (GOLD) se basa principalmente en las …

The use of extracorporeal membrane oxygenation (ECMO) for respiratory failure in adults is
growing rapidly, driven in large part by advances in technology, which have made ECMO …

Introduction: The number of patients with pulmonary disease caused by non-tuberculous
mycobacteria (NTM) is increasing globally. Poor resistance against infections, for example …

Objective. Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic
pulmonary fibrosis (IPF). The pathological pathways involved in fibrogenesis in IPF and …

Lung transplantation can improve quality of life and prolong survival for individuals with end-
stage lung disease, and many advances in the realms of both basic science and clinical …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity
and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung …

Background Frailty, including low muscle mass, is an emerging risk factor for poor outcomes
after lung transplant. The sarcopenia index (SI)—(serum creatinine value/cystatin C value)× …

Early mobilization of critically ill patients is increasingly being recognized as not only safe
and feasible, but also as a potential means of optimizing outcomes in the intensive care unit …